DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells M Carlsten, NK Björkström, H Norell, Y Bryceson, T van Hall, ... Cancer research 67 (3), 1317-1325, 2007 | 312 | 2007 |
Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells M Carlsten, H Norell, YT Bryceson, I Poschke, K Schedvins, ... The Journal of Immunology 183 (8), 4921-4930, 2009 | 296 | 2009 |
Natural killer cell-mediated immunosurveillance of human cancer KJ Malmberg, M Carlsten, A Björklund, E Sohlberg, YT Bryceson, ... Seminars in immunology 31, 20-29, 2017 | 269 | 2017 |
Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens RW Childs, M Carlsten Nature reviews Drug discovery 14 (7), 487-498, 2015 | 269 | 2015 |
IFN-γ protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism KJ Malmberg, V Levitsky, H Norell, CT De Matos, M Carlsten, K Schedvins, ... The Journal of clinical investigation 110 (10), 1515-1523, 2002 | 255 | 2002 |
Genetic manipulation of NK cells for cancer immunotherapy: techniques and clinical implications M Carlsten, RW Childs Frontiers in immunology 6, 266, 2015 | 233 | 2015 |
Complete remission with reduction of high-risk clones following haploidentical NK-cell therapy against MDS and AML AT Björklund, M Carlsten, E Sohlberg, LL Liu, T Clancy, M Karimi, ... Clinical Cancer Research 24 (8), 1834-1844, 2018 | 182 | 2018 |
Checkpoint inhibition of KIR2D with the monoclonal antibody IPH2101 induces contraction and hyporesponsiveness of NK cells in patients with myeloma M Carlsten, N Korde, R Kotecha, R Reger, S Bor, D Kazandjian, ... Clinical Cancer Research 22 (21), 5211-5222, 2016 | 172 | 2016 |
The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies T Dosani, M Carlsten, I Maric, O Landgren Blood cancer journal 5 (4), e306-e306, 2015 | 148 | 2015 |
Natural killer cells in myeloid malignancies: immune surveillance, NK cell dysfunction, and pharmacological opportunities to bolster the endogenous NK cells M Carlsten, M Järås Frontiers in immunology 10, 2357, 2019 | 135 | 2019 |
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma N Korde, M Carlsten, MJ Lee, A Minter, E Tan, M Kwok, E Manasanch, ... Haematologica 99 (6), e81, 2014 | 135 | 2014 |
Estimation of the Size of the Alloreactive NK Cell Repertoire: Studies in Individuals Homozygous for the Group A KIR Haplotype C Fauriat, S Andersson, AT Bjorklund, M Carlsten, M Schaffer, ... The Journal of Immunology 181 (9), 6010-6019, 2008 | 133 | 2008 |
Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers S Ito, CM Bollard, M Carlsten, JJ Melenhorst, A Biancotto, E Wang, J Chen, ... Molecular therapy 22 (7), 1388-1395, 2014 | 132 | 2014 |
The core promoter of human thioredoxin reductase 1: cloning, transcriptional activity, and Oct-1, Sp1, and Sp3 binding reveal a housekeeping-type promoter for the AU-rich … AK Rundlöf, M Carlsten, ESJ Arnér Journal of Biological Chemistry 276 (32), 30542-30551, 2001 | 128 | 2001 |
NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy KJ Malmberg, YT Bryceson, M Carlsten, S Andersson, A Björklund, ... Cancer Immunology, Immunotherapy 57, 1541-1552, 2008 | 121 | 2008 |
Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome M Carlsten, BC Baumann, M Simonsson, M Jädersten, AM Forsblom, ... Leukemia 24 (9), 1607-1616, 2010 | 120 | 2010 |
Efficient mRNA-based genetic engineering of human NK cells with high-affinity CD16 and CCR7 augments rituximab-induced ADCC against lymphoma and targets NK cell migration … M Carlsten, E Levy, A Karambelkar, L Li, R Reger, M Berg, MV Peshwa, ... Frontiers in immunology 7, 105, 2016 | 111 | 2016 |
Coordinated expression of DNAM-1 and LFA-1 in educated NK cells M Enqvist, EH Ask, E Forslund, M Carlsten, G Abrahamsen, V Béziat, ... The Journal of Immunology 194 (9), 4518-4527, 2015 | 105 | 2015 |
Sugar free: novel immunotherapeutic approaches targeting siglecs and sialic acids to enhance natural killer cell cytotoxicity against cancer J Daly, M Carlsten, M O'Dwyer Frontiers in immunology 10, 1047, 2019 | 94 | 2019 |
Frequent Loss of HLA-A2 Expression in Metastasizing Ovarian Carcinomas Associated with Genomic Haplotype Loss and HLA-A2-Restricted HER-2/neu-Specific … H Norell, M Carlsten, T Ohlum, KJ Malmberg, G Masucci, K Schedvins, ... Cancer research 66 (12), 6387-6394, 2006 | 80 | 2006 |